• Vaccine Name: UV Inactivated SARS-CoV vaccine
• Target Pathogen: SARS-CoV
• Target Disease: Severe Acute Respiratory Syndrome (SARS)
• Type: Live, attenuated vaccine
• Status: Licensed
• Host Species for Licensed Use: None
• Host Species as Laboratory Animal Model: mouse
• Antigen: whole virus(Iwata-Yoshikawa et al., 2014)
• Immunization Route: Intramuscular injection (i.m.)
• Description: Ultraviolet radiation applied to SARS virus. Vaccine causes eosinophilic immunopathology to SARS while providing protection (Iwata-Yoshikawa et al., 2014)

Mouse Response

• Host Strain: BALB/c
• Host age: 10 weeks (Iwata-Yoshikawa et al., 2014)
• Host gender: Female (Iwata-Yoshikawa et al., 2014)
• Vaccination Protocol: 10 μg UV-V subcutaneously injected in back and reimmunized 6 to 7 weeks later (Iwata-Yoshikawa et al., 2014)
• Immune Response: Induced neutralizing antibodies, Lymphocyte infiltration, Upregulation of IL-4 and CCL24, CD11b+ cells upregulated genes associated with eosinophil induction (Iwata-Yoshikawa et al., 2014).
• Side Effects: Eosinophil infiltration present in the lungs (Iwata-Yoshikawa et al., 2014)
• Challenge Protocol: 10 week old BALB/c mice were vaccinated with 10 μg UV-V and boosted 6 weeks later. Four weeks afterwards, the animals were inoculated in the left nostril with 106.5 TCID50 in 30 μl of F-musX(Iwata-Yoshikawa et al., 2014).
• Efficacy: Most mice survived challenge after weight loss and respiratory disease (Iwata-Yoshikawa et al., 2014)